SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-027348
Filing Date
2020-05-28
Accepted
2020-05-28 16:50:05
Documents
12
Period of Report
2020-05-27
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K aimt-8k_20200527.htm   iXBRL 8-K 55471
  Complete submission text file 0001564590-20-027348.txt   185639

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aimt-20200527.xsd EX-101.SCH 5772
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20200527_lab.xml EX-101.LAB 19478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20200527_pre.xml EX-101.PRE 11627
6 EXTRACTED XBRL INSTANCE DOCUMENT aimt-8k_20200527_htm.xml XML 3557
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37519 | Film No.: 20921889
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences